Apotex Inc, a Canada-based global health company, announced on Thursday the commercial launch in Canada of Apo-Semaglutide Injection, a generic equivalent of Ozempic.
The product will be available across Canada within the coming weeks.
Apo-Semaglutide Injection is approved in 2 mg and 4 mg prefilled pen formats, providing 0.25 mg or 0.5 mg doses (2 mg pen; 0.68 mg/mL) and 1 mg doses (4 mg pen; 1.34 mg/mL).
Administered using a prefilled pen, with instructions for use consistent with brand-name semaglutide, Apo-Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus to improve glycaemic control, in combination with diet and exercise.
Apo-Semaglutide Injection was developed in partnership with Orbicular Pharmaceutical Technologies.
Dexcom launches Dexcom Flex CGM system for Type 2 diabetes patients in Germany
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Bayer to acquire Perfuse Therapeutics in USD2.45bn deal to expand ophthalmology pipeline
ZYUS Life Sciences receives second US pain management patent
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cirius Therapeutics introduces gestational diabetes initiative
Boehringer Ingelheim's survodutide phase 3 data show significant weight loss in obesity trial
AOTI reports strong real-world outcomes for TWO2 wound therapy
Ascletis completes enrolment for US Phase II study of ASC30 in diabetes
Renalytix advances kidneyintelX.Dkd scale-up with laboratory expansion and CE submission
FDA expands approval of Sanofi's Tzield for early-stage type 1 diabetes in young children
EKF Diagnostics acquires Beep Insights technology to expand sports performance offering
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval